A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Verve Therapeutics, Inc.
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- HEART-3
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 175
- sponsor
- Verve Therapeutics, Inc.
- conditions
- Atherosclerosis; Cardiovascular Disease; Hypercholesterolemia
- interventions
- DRUG: VERVE-102; DRUG: Placebo
- start date
- 2026-10-01
- start date type
- ESTIMATED
- primary completion date
- 2028-08-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07839936
- Published
- Sep 24, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07839936
- Categories
- Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials